drugset / Trial / NCT02248792

Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.

NCT02248792

Phase 4 Unknown 50 enrolled Narayana Medical College & Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.

Timeline

Start
2013-11
Primary completion
2015-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 10 mg Oral
Subject Methotrexate Small molecule 25 mg Oral

Indications